249 Shares in Eli Lilly and Company $LLY Bought by Benchmark Investment Advisors LLC

Benchmark Investment Advisors LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 249 shares of the company’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Orion Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 2.5% during the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company’s stock valued at $1,243,000 after purchasing an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in shares of Eli Lilly and Company by 4.1% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company’s stock valued at $49,993,000 after purchasing an additional 2,568 shares in the last quarter. Finally, Breed s Hill Capital LLC lifted its holdings in shares of Eli Lilly and Company by 212.0% during the fourth quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company’s stock valued at $1,101,000 after purchasing an additional 969 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.1%

LLY stock opened at $732.41 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $969.65. The business’s 50-day moving average is $748.68 and its two-hundred day moving average is $786.10. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $693.20 billion, a price-to-earnings ratio of 47.87, a P/E/G ratio of 1.02 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Guggenheim lowered their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. UBS Group lowered their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $950.17.

Insiders Place Their Bets

In related news, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.